What's happening
This bill classifies Xylazine and its chemical forms as a Schedule III depressant under New York public health law.
Why it matters
Classifying Xylazine as a Schedule III depressant places it under stricter regulatory controls. , making it harder to obtain or distribute without proper authorization. This could help curb its misuse, particularly in the context of rising concerns about its role in drug overdoses and illicit mixtures with opioids.
Anyone handling, prescribing, or dispensing Xylazine will face new legal requirements. including potential licensing, recordkeeping, and storage regulations—similar to those for other controlled substances. This may impact veterinarians, medical researchers, and suppliers who use Xylazine legitimately.
Law enforcement and public health officials will have clearer authority to address Xylazine-related offenses. , potentially leading to more targeted interventions and prosecutions related to its illegal distribution or misuse. This change could also facilitate better tracking and response to trends in drug use and overdoses involving Xylazine.
Albany, before your first meeting.
Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.
Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.
Headline styles
Restrict Xylazine Use
Plain English, a few words. Used as the page title.
Sponsors
Senator · Senate District 42
No co-sponsors yet.
History
- Referred to health
- Print number 5439a
- Amend and recommit to health
- Referred to health
Companion bill
The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.
Restrict Xylazine as Depressant
In Assembly Committee · Health · Sponsor Carrie Woerner
Full text
1 pageUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗
STATE OF NEW YORK
5439--A
2023-2024 Regular Sessions
IN SENATE
March 6, 2023
Introduced by Sen. SKOUFIS -- read twice and ordered printed, and when printed to be committed to the Committee on Health -- committee discharged, bill amended, ordered reprinted as amended and recommitted to said committee
AN ACT to amend the public health law, in relation to designating Xylazine as a schedule III depressant
The People of the State of New York, represented in Senate and Assembly, do enact as follows:
Section 1. Subdivision (c) of schedule III of section 3306 of the public health law is amended by adding a new paragraph 15 to read as follows:
(15) Xylazine (N-(2,6-dimethylphenyl)-5,6-dihydro-4H-1,3 thiazin-2- amine), including its salts, isomers and salts of isomers whenever the existence of such salts, isomers and salts of isomers is possible within the specific chemical designation.
§ 2. This act shall take effect on the ninetieth day after it shall have become a law.
EXPLANATION--Matter in italics (underscored) is new; matter in brackets
[ ] is old law to be omitted.
LBD09888-02-3
Reflowed for reading: line numbers and page breaks removed. Cite the official text.
Sponsor's memo
Title of bill
An act to amend the public health law, in relation to designating Xyla- zine as a schedule III depressant
Purpose or general idea of bill
This bill designates xylazine as a schedule III-controlled substance
Summary of provisions
Section 1: amends subdivision (c) of schedule III of section 3306 of the public health law, regarding schedules of controlled substances, to add a new paragraph 15 to include Xylazine N(2,6-dimethylpheny1)-5,6-dihydro-4H-1,3 thiazin-2-amine) as a schedule III controlled substance.
Section 2: establishes the effective date.
Difference between original and amended version (if applicable)
Section 1 expands the reference to xylazine to include "salts, isomers and salts of isomers".
Justification
Xylazine is a veterinary sedative primarily used on horses during substantially painful procedures such as castration and dental work. Much like ketamine, which was classified under New York law as a sched- ule III controlled substance in 1997, the drug is being diverted for human use causing severe adverse health effects. The Department of Health reached out to local EMS warning them of the dangers of xylazine- laced heroin, which has emerged as the most recent threat in New York state's battle against heroin fentanyl. Both heroin and fentanyl dealers are using this dangerous substance to "enhance" and "bulk up" product, thus increasing demand and dependency.
The use of xylazine can lead to hypotension and bradycardia, and when combined with central nervous system depressants, such as benzodiaze- pines or alcohol, it can significantly depress vital functions and increase the risk of overdose and death. Xylazine is sometimes used as an adulterant and combined with opioids and recreational drugs; however, it has no antidote and, as a notice released by the FDA to health care providers in November 2022 warns, 1 the use of naloxone "may not be able to reverse its effects." The heroin-xylazine combination is so potent that it can take multiple doses of naloxone to revive an overdose victim, and even this regime is not guaranteed to be effective. Adding xylazine to the controlled substance schedule can ensure proper safe- guards against diversion and help combat the heroin epidemic currently plaguing the state.
Prior legislative history
2018: S.300 - Referred to Health.
2017: S.300 - Passed Senate. 2016: S.7397 - Passed Senate.
Fiscal implications for state and local governments
None to the state.
Effective date
This act shall take effect on the ninetieth day after it shall have become a law.
1 FDA alerts health care professionals of risks to patients exposed to xylazine in illicit drugs. November 8, 2022. U.S. Food and Drug Adminis- tration. Retrieved March 14, 2023, from https://www.fda.gov/drugs/drug-safety-and- availahility/fda-alerts- health -care-professionals-risks-patients- exposed-xylazine-illicit- drugs
Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.